Biotech Values

[floblu14]

BARRON'S - After Pharmacyclics, Who’s Next in Biotech M&A?
March 5, 2015, 11:50 A.M. ET

We believe that partnership and acquisition (P&A) activity is likely to remain a key feature of newsflow and excess returns for investors in the biopharma industry…We highlight 8 small and mid-cap biopharma companies and 2 larger biopharma companies with attractive assets, identified by a hybrid value/fundamental screen. New names include Aegerion Pharmaceuticals (AEGR), AMAG Pharmaceuticals (AMAG), Hyperion Therapeutics (HPTX), Impax Laboratories (IPXL), Medicines Company (MDCO), Mallinckrodt (MNK), Momenta Pharmaceuticals (MNTA), Mylan (MYL), Perrigo (PRGO), and United Therapeutics (UTHR). Two interesting observations regarding this year’s list: 1) Both Medicine Company and United Therapeutics have appeared on previous lists. We believe this reflects their ongoing undervaluation due to product life-cycle concerns; 2) We believe four of the spec pharma companies on our list are seeking accretive M&A, indicating they may be buyers as well as potentially sold.

http://blogs.barrons.com/stockstowatchtoday/2015/03/05/after-pharmacyclics-whos-next-in-biotech-ma/